Reimbursement Consulting Services for Medical Device, Diagnostics & Digital Therapeutics Companies
Public Comment for the CMS Proposed Medicare Payment rates for the Hospital Outpatient and Ambulatory Surgical Center
Public Comment for the CMS Proposed Medicare Payment rates for the Hospital Outpatient and Ambulatory Surgical Centeradmin2022-10-11T07:16:42-07:00
Why this Newsletter
The public comment period ends September 13, 2022 for the Centers for Medicare and Medicaid Services (CMS) proposed Hospital Outpatient Prospective Payment System (OPPS) and Ambulatory Surgical Center (ASC) payment rates for calendar year (CY) 2023 (October 1, 2022- September 30, 2023).
In the proposed rule there are three notable provisions. First to increase payment rates by 2.7% for hospitals and ASCs meeting applicable quality reporting requirements for CY 2023, using the June 2020 cost report and CY 2021 data to set CY 2023 OPPS and ASC payment system rates. Second to provide an additional 5% payment for each covered outpatient department service furnished by a rural emergency hospital. Third CMS is soliciting comments on the eight applications for device pass-through payments it received.
For the full list of proposed changes, you can read the fact sheet here, press release here and proposed rule here.
About Rowinski Group
Founded in 2004, Rowinski Group LLC is a reimbursement and healthcare payer data analytics consulting firm for medical device, digital health, diagnostics, and imaging companies. Rowinski Group main US office is in San Francisco, California with offices at selected client locations.
Rowinski Group has two core service offerings; 1) Secure codes, coverage and/or reimbursement on behalf of our company clients and, 2) Apply healthcare payer data analytics to help companies solve business matters like responding to questions from the FDA and Medicare and Private healthcare payers, helping companies to prioritize and identify, for FDA and company sponsored studies, US based clinical sites based on carefully selected criteria.
Through these service offerings Rowinski Group helps U.S. and international companies build their U.S. market share for the medical technology they are developing for and selling in the US market.
Rowinski Group is a US-based nationally certified Women’s Business Enterprise (WBE). This certification is relevant for companies (publicly traded, privately held and not-for-profit) and universities who use supplier diversity programs to award contracted services.